CA Patent

CA3167017A1 — Treatment of paroxysmal nocturnal hemoglobinuria

Assigned to Apellis Pharmaceuticals Inc · Expires 2021-07-15 · 5y expired

What this patent protects

Methods and compositions for treatment of paroxysmal nocturnal hemoglobinuria are described. In some aspects, the disclosure features a method of treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising subcutaneously administering to the subject pe…

USPTO Abstract

Methods and compositions for treatment of paroxysmal nocturnal hemoglobinuria are described. In some aspects, the disclosure features a method of treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising subcutaneously administering to the subject pegcetacoplan.

Drugs covered by this patent

Patent Metadata

Patent number: CA3167017A1
Jurisdiction: CA
Classification: —
Expires: 2021-07-15
Drug substance claim: No
Drug product claim: No
Assignee: Apellis Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.